Molecular Determinants of the Cytotoxicity of Platinum Compounds: The Contribution of in Silico Research

Cancer Research

Volumn 64, Issue 1, 2004, Pages 356-362

  Vekris, Antoine ^a   Meynard, Delphine ^b   Haaz, Marie Christine ^a   Bayssas, Martine ^c   Bonnet, Jacques ^b   Robert, Jacques ^b  

^a DiGEM S A   (France)

^b INSTITUT BERGONIÉ   (France)

^c DEBIOPHARM SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; MELPHALAN; MOLECULAR MARKER; MYC PROTEIN; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN BCL XL; PROTEIN P53; RAS PROTEIN; TETRAPLATIN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESEARCH; COMPUTER MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE; CELL SURVIVAL; CISPLATIN; DATABASES, FACTUAL; GENE EXPRESSION REGULATION; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); ORGANOPLATINUM COMPOUNDS; PLATINUM COMPOUNDS; UNITED STATES;

EID: 1642453792     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2258     Document Type: Article

References (40)

1. Rosenberg, B. Fundamental studies with cisplatin. Cancer (Phila.). 55: 2303-2316, 1985.
2. Mayes, D. M., Cvitkovic, E., Golberg, R. B., Scheiner, E., Nelson, L., and Krakoff, I. H. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer (Phila.), 39: 1372-1281, 1977.
3. Hamilton, T. C., O'Dwyer, P. J., and Ozols, R. F. Platinum analogues in preclinical and clinical development. Curr. Opin. Oncol., 5: 1010-1016, 1993.
4. Lebwohl, D., and Canetta, R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur. J. Cancer, 34: 1522-1534, 1998.
5. Lokich, J., and Anderson, N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol., 9: 13-21, 1998.
6. Misset, J. L., Bleiberg, H., Sutherland, W., Bekradda, M., and Cvitkovic, E. Oxaliplatin clinical activity: a review. Crit. Rev. Oncol. Hematol., 35: 75-93, 2000.
7. Tutsch, K. D., Arzoomanian, R. Z., Alberti, D., Tombes, M. B., Feirabend, C., Robins, H. L., Spriggs, D. R., and Wilding, G. Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812). Investig. New Drugs. 17: 63-72, 1999.
8. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff. A., Gray-Goodrich, M., Campbell, H., Mayo, J., and Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Nat. Cancer Inst. (Bethesda), 83: 757-766, 1991.
9. Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., and Fojo, T. Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute anticancer drug screen panel. Biochem. Pharmacol., 52: 1855-1865, 1996.
10. Scherf, U., Ross, D. J., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K., Reinhold, W. C., Myers, T. C., Andrews. D. T., Scudiero, D. A., Eisen, M. B., Sausville, E. A., Pommier, Y., Botstein, D., Brown, P. O., and Weinstein, J. N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet., 24: 236-244, 2000.
11. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
12. Sklar, M. D. Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transfected by ras oncogene. Cancer Res., 48: 793-797, 1988.
13. Perez, R. P. Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer. 34: 1534-1542, 1998.
14. Niedner, H., Christen, R., Lin, X., Kondo, A., and Howell, S. B. Identification of genes that mediate sensitivity to cisplatin. Mol. Pharmacol., 60: 1153-1160, 2001.
15. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., and Howell, S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56: 4881-4886, 1996.
16. Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., and Anderson, M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA, 89: 3070-3074, 1992.
17. Mistry, P., Kelland, L. R., Abel, G., Sidhar, S., and Harrap, K. R. The relationship between glutathione S-transferase and cytotoxicity of platinum drugs and metphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer, 64: 215-220, 1991.
18. Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., and Lazo, J. S. Overexpression of metalothionein confers resistance to anticancer drugs. Science (Wash. DC), 241: 1813-1815, 1988.
19. Chen, Z. S., Mutoh, M., Sumizaw, T., Furukawa, T., Haraguchi, M., Tani, A., Saijo, N., Kondo, T., and Akiyama, S. An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells. Exp. Cell Res., 240: 312-320, 1998.
20. Chatterjee, D., Liu, C. J. T., Northey, D., and Teicher, B. A. Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors. Cancer Chemother. Pharmacol., 35: 423-431, 1995.
21. Niimi, S., Nakagawa, K., Yokota, J., Tsunokawa, Y., Nishio, K., Terashima, Y., Shibuya, M., Terada, M., and Saijo, N. Resistance to anticancer drugs in NIH 3T3 cells transfected with c-myc and/or c-H-ras genes. Br. J. Cancer, 63: 237-241, 1991.
22. Moorehead, R. A., and Singh, G. Influence of the proto-oncogene c-fos on cisplatin sensitivity. Biochem. Pharmacol., 59: 337-345, 2000.
23. Eliopoulos, A. G., Kerr, D. J., Herod, J., Hodgkins, L., Krajewski, S., Reed, J. C., and Young, L. S. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene, 11: 1217-1228, 1995.
24. Miyake, H., Hanada, N., Nakamura, H., Kagawa, S., Fujiwara, T., Hara, I., Eto, H., Gohji, K., Arakawa, S., Kamidono, S., and Saya, H. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene, 16: 933-943, 1998.
25. Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed. J. C., and Zunino, F. Association between cisplatin resistance and mutations of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res., 56: 556-562, 1996.
26. Raymond, E., Faivre, S., Chaney, S., Woynarowski, J., and Cvitkovic, E. Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther., 1: 227-235, 2002.
27. Hector, S., Bolanowska-Higdon, W., Zdanowicz, J., Hitt, S., and Pendyala. L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother. Pharmacol., 48: 398-406, 2001.
28. Mishima, M., Samimi, G., Kondo, A., Lin, X., and Howell, S. B. The cellular pharmacology of oxaliplatin resistance. Eur. J. Cancer, 38: 1405-1412, 2002.
29. Amould, S., Hennebelle, I., Canal, P., Bugat, R., and Guichard, S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur. J. Cancer, 39: 112-119, 2003.
30. Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y. P., Uetake, H., Danenberg, K. D., Groshen, S., Tsao-Wei, D. D., Danenberg, P. V., and Lenz, H. J. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol., 19: 4298-4304, 2001.
31. Marth, C., Widschwendter, M., Kærn, J., Jørgensen, N. P., Windbichler, G., Zeimet, A. G., Tropé, C., and Daxenbichler, G. Cisplatin resistance is associated with reduced interferon-γ-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells. Br. J. Cancer. 76: 1328-1332, 1997.
32. Zarnbutsu, H., Ohniski, Y., Tsunoda, T., Furukawa, Y., Katagiri, T., Ueyama, Y., Tamaoki, N., Nomura, T., Kitahara, O., Yanagawa, R., Hirata, K., and Nakamura, Y. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res., 62: 518-527, 2002.
33. Dan, S., Tsunoda, T., Kitahara, O., Yamagawa, R., Zembutsu, H., Katagori, T., Yamazaki, K., Nakamura, Y., and Yamori, T. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res., 62: 1139-1147, 2002.
34. Staunton, J. E., Slonim, D. K., Coller, H. A., Tamayo, P., Angelo, M. J., Park, J., Scherf, U., Lee, J. K., Reinhold, W. O., Weinstein, J. N., Mesirov, J. P., Lander, E. S., and Golub, T. R. Chemosensitivity prediction by transcription profiling. Proc. Natl. Acad. Sci. USA, 98: 10787-10792, 2001.
35. Wallqvist, A., Rabow. A. A., Shoemaker, R. H., Sausville, E. A., and Covell, D. G. Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology. Mol. Cancer Ther., 1: 311-320, 2002.
36. Brown, J. M. NCI's anticancer drug screening program may not be selecting for clinically active compounds. Oncol. Res., 9: 213-215, 1997.
37. Brown, J. M., and Wouters, B. G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res., 59: 1391-1399, 1999.
38. Eliopoulos, A. G., Kerr, D. J., Maurer, H. R., Hilgard, P., and Spandidos, D. A. Induction of the c-myc but not the cH-ras promoter by platinum compounds. Biochem. Pharmacol., 50: 33-38, 1995.
39. Koo, H. M., Monks, A., Mikheev, A., Rubinstein, L. V., Gray-Goodrich, M., McWilliams, M. J., Alvord, W. G., Oie, H. K., Gazdar, A. F., Paull, K. D., Zarbl, H., and Vande Woude, G. F. Enhanced sensitivity to 1-β -D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res., 56: 5211-5216, 1996.
40. Weinstein, I. B. Addiction to oncogenes-the Achilles heal of cancer. Science (Wash, DC), 297: 63-64, 2002.